Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...

New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.

WASHINGTON (DC News Now) — A new blood test may make it much easier and cheaper to screen for signs of colon cancer. Test manufacturer Guardant said the Food and Drug Administration (FDA) approved its ...

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

Colonoscopy remains a cornerstone of colorectal cancer prevention, but GI leaders say the procedure’s role, and the business model built around it, is shifting fast. Here’s what five leaders have told ...

According to Cologuard, made by Wisconsin-based Exact Sciences, there are three primary reasons why you may receive a testing kit in the mail without ordering it yourself: your doctor or health care ...

INDIANAPOLIS (WISH) – This week, the United States Food and Drug Administration approved Guardant’s Shield blood test to screen for colon cancer in average-risk Americans 45 to 75 years old.

For years, the gold standard in screening for colon cancer has been a colonoscopy. But a colonoscopy is a medical procedure that involves length prep work, along with being put under, making it ...

Colon cancer is on the rise in younger people, which is why testing guidelines recommend testing starting at 45 for those at average risk. To stop colon cancer, it’s important to know when and how to ...

Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...

For 10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.